CP, Dr Jedd Wolchok listed as a Scientific Advisor for Tizona, though one has to scroll all the way down he is last name listed...and my overall gut reaction of this was they bring in Dr Wolchok to find what he says about PS Targeting possibly....
Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.
OUR APPROACH
Tizona develops next-generation immunotherapies The successful development of immunotherapies represents one of the most important and exciting breakthroughs in cancer. Recent approvals of checkpoint inhibitors provide evidence that the immune system is capable of recognizing cancerous cells and eradicating them. These checkpoint inhibitors can achieve complete, durable remissions and help patients live longer. Yet, despite this progress, existing immunotherapies are effective in a relatively small number of patients and types of cancer.
Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity:
Immune suppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tolerogenic dendritic cells (DCs) Inhibitory / suppressive cytokines and metabolic pathways
Our distinct approach to Tumor Immunotherapy CONVENTIONAL IMMUNOTHERAPY APPROACHES T cell Priming, Activation & Proliferation Checkpoint inhibitors (e.g., CTLA4, PD-1) Coactivators (e.g., 4-1BB) Vaccines (peptide, DNA, DC, artificial APCs, etc.) Oncolytic Viruses Cytokines (IL-12, IL-15, IL-21) TIZONA’S CURRENT APPROACH Immunosuppressive Tumor Microenvironment Tregs TAMs, MDSCs, tolerogenic DCs Inhibitory cytokines OPPORTUNISTIC AREA OF INTEREST T cell Trafficking & Infiltration Chemokines Immuno-repellent factors OUR TEAM
Tizona’s expert team of scientific advisors, board of directors and accomplished team position the company to become a leader in next generation immunotherapy development.
Pablo J. Cagnoni, M.D. President & Chief Executive Officer Pablo is President and CEO of Tizona. Over of the course of his career as an oncologist and pharmaceutical... Full Bio
Jeremy Bender, Ph.D., M.B.A. Chief Operating Officer Jeremy joined Tizona as COO in July of 2015. In his role, he oversees the company’s finance, operations, alliance,... Full Bio
Courtney Beers, Ph.D. Vice President, Immunology Courtney is the Vice President of Cancer Immunotherapy for Tizona. She is leading discovery and development work on Tizona’s... Full Bio
John Corbin, Ph.D. Vice President, Antibody Development John joined Tizona as Vice President of Antibody Development in 2016. In his role, he is responsible for antibody... Full Bio
Svetlana Lucas, Ph.D. Vice President, Business Development Svetlana joined Tizona Therapeutics as Vice President of Business Development in July of 2015. In her role, she is... Full Bio BOARD OF DIRECTORS
Luke Evnin, Ph.D. Tizona Chairman and Co-Founder and Managing Director of MPM Capital Pablo J. Cagnoni, M.D. President & Chief Executive Officer of Tizona Theraputics Shelley Chu, M.D., Ph.D. Partner at Abingworth Jean George General Partner at Lightstone Ventures George Golumbeski, Ph.D. Executive Vice President of Business Development, Celgene Corporation Daniel J. Hicklin, Ph.D. President and Chief Executive Officer of Potenza Therapeutics, Nina Kjellson General Partner at Canaan Partners Arnold Oronsky, Ph.D. General Partner of InterWest Partners SCIENTIFIC CO-FOUNDERS & ADVISORY BOARD MEMBERS
Ana Anderson, Ph.D. Charles G. Drake, M.D., Ph.D. Vijay K. Kuchroo, D.V.M., Ph.D. Wayne A. Marasco, M.D., Ph.D. Drew Pardoll, M.D., Ph.D. George Plitas, M.D. Dario Vignali, Ph.D. Jedd Wolchok, M.D., Ph.D.
.....Though I know JUNO failed (without Bavituximab) when many patients died and when JUNOs trial failed that was when it was announced soon after that PS Targeting going into the lab of Dr Wolchok..
When I said Dr Wolchok backing Tizona I am under the impression they brought Dr Wolchok on after Tizona realized Dr Wolchok was in the Peregrine's camp..
But you are correct about Tizona website not good....tough to read and I can't find news "when" exactly Dr Wolchok shows up there and recruited
